<DOC>
	<DOCNO>NCT00920920</DOCNO>
	<brief_summary>Background : The standard treatment locally advanced cervical cancer radio-chemotherapy include external beam radiotherapy ( EBRT ) , brachytherapy ( BT ) concomitant chemotherapy weekly Cisplatin . While image base conformal EBRT routinely use , prescription reporting BT still base specific dose point define 2D . Thus , several decade BT dose often prescribe report Manchester point A define accord different tradition . Recently , work group GEC-ESTRO publish recommendation contour tumour target organ risk ( OAR ) well dose volume parameter report image guide BT definitive radiotherapy locally advanced cervical cancer . These recommendation mainly derive retrospective single institution experience MRI base intracavitary BT . The major advantage technique possibility conform dose give BT regard volume ( 3D ) time ( 4D ) . Thus , repetitive imaging perform BT implant possible adapt dose give BT anatomy individual patient take account position OAR also tumour regression often obtain precede EBRT chemotherapy . Based experience collect far , image base BT approach expect major impact clinical outcome concomitant decrease rate local failure morbidity . Aims : - To introduce MRI base 3D-4D BT locally advance cervical cancer multicenter set within frame prospective observational study . - To establish bench-mark clinical outcome image base BT large patient population respect local control , survival , morbidity QoL - To establish reference material regard image base DVH parameter accord guideline GEC ESTRO work group . - To correlate image base DVH parameter CTV OAR outcome - To develop prognostic predictive statistical model clinical outcome include volumetric , dosimetric , clinical biological risk factor - To establish radiobiological parameter estimate allow precise risk estimation individual patient aid development new treatment protocol</brief_summary>
	<brief_title>An International Study Magnetic Resonance Imaging ( MRI ) -Guided Brachytherapy Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>A prospective observational multicenter study perform patient locally advanced cervical cancer consider potentially curable definitive radio- ( chemo ) therapy . The patient divide analyzed three stratum accord risk recurrence : 1 . Small tumours 2 . Large tumour favourable response 3 . Large tumour unfavourable response initial radio- ( chemo ) therapy . A clinical local failure validate MRI topographically correlate MRI base BT target ( HR CTV IR-CTV ) dose volume parameter treatment plan . It classify `` inside '' , `` edge '' , `` outside '' . Major event regard morbidity report use 3D image information integrate e.g . clinical examination , endoscopy MRI . The location organ damage ( i.e . fistula ) identify 3D correlation dose volume parameter affect region investigate . Specific Aims - To assess prospectively outcome disease ( local control , survival ) , morbidity QoL life apply appropriate clinical , image QoL protocol . - To test three group represent different risk recurrence : small tumour ; large tumour favourable response ; large tumour unfavourable response initial radio- ( chemo ) therapy . - To correlate local control ( survival ) dose volume parameter GTV CTV overall cohort 3 different risk group establish hazard ratio dose effect curve primary tumour . - To correlate outcome data dose volume parameter different OAR ( rectum , sigmoid , bladder ) establish hazard ratio dose effect curve OAR . - To correlate QoL outcome morbidity outcome . - To quantify change DVH parameter obtain image guide dose optimization BT individual patient . - To compare volumetric data GTV CTV diagnosis treatment relate dose volume parameter within 3 different risk group overall patient cohort . - To evaluate indicator quality assessment throughout whole study period order define systematic random variation different indicator ( e.g . contouring , applicator reconstruction , dose volume assessment ) . - To validate clinical outcome data radiobiological equivalence calculation use assess dose volume parameter gynaecological radiotherapy . - To test GYN GEC ESTRO recommendation BT cervical cancer feasible multi-centre setting .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Cancer uterine cervix consider suitable curative treatment definitive radio ( chemo ) therapy include MRI guide BT Positive biopsy show squamouscell carcinoma , adenocarcinoma adenosquamous cell carcinoma uterine cervix . Staging accord FIGO TNM guideline MRI pelvis diagnosis perform MRI , CT PETCT retroperitoneal space abdomen diagnosis perform MRI applicator place time ( first ) BT perform Paraaortic metastatic node L1L2 allow Patient informed consent Other primary malignancy except carcinoma situ cervix basal cell carcinoma skin Metastatic disease beyond paraaortic region ( L1L2 ) Previous pelvic abdominal radiotherapy Previous total partial hysterectomy Combination preoperative radiotherapy surgery Patients receive BT Patients receive EBRT Patients receive neoadjuvant chemotherapy Contra indication MRI Contra indication BT Active infection severe medical condition endanger treatment delivery Pregnant , lactate childbearing potential without adequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>3D-4D MRI-based Brachytherapy</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Multicenter Clinical Study</keyword>
	<keyword>Locally advanced cervical cancer</keyword>
</DOC>